Mebufotenin Nasal Spray Shows Promise for Depression
A new phase 2b trial finds that a synthesized 5-MeO-DMT spray improves depression scores in patients.
Updated on Oct. 26, 2026 in Substance Abuse
Live Poll
Should psychedelic-based drugs be approved as standard treatments for treatment-resistant depression?
Researchers published clinical trial results in JAMA showing that a mebufotenin nasal spray can provide antidepressant benefits for up to eight weeks. The study tested different dosages on 193 participants with moderate to severe depression across Australia, Europe, and the US.
Why it matters
Scientists are testing the drug to determine if it can serve as a safe and efficient treatment option for individuals with difficult-to-treat depression. The trial focused on finding the most effective dosage to carry forward into larger studies.
The clinical trial included 193 participants who received dosages of 0.3 mg, 8 mg, or 12 mg. The 12 mg dose yielded a 5.3-point improvement over the low-dose baseline, while the 8 mg dose provided a 6.2-point improvement.
The players
JAMA
This is a peer-reviewed medical journal published by the American Medical Association that frequently features original research and clinical trial results.
The details
Participants underwent dosing sessions involving psychological support protocols modeled after existing psychedelic therapies. Most patients were ready to leave the treatment environment within two hours, with benefits typically emerging two days after the session.
Timeline
October 26, 2026: Clinical trial results were published in JAMA.
2 days post-dose: Patients typically began experiencing antidepressant benefits.
8 weeks: Duration of continued antidepressant benefits reported by participants.
Health Landscape
This study contributes to the expanding body of research exploring the clinical utility of psychedelic compounds for psychiatric care. It follows the structural standards for set and setting established by the FDA's psychedelic medicine guidance for clinical trials.
Patients currently struggling with difficult-to-treat depression may gain future access to a rapid-acting treatment option if the drug clears further testing. However, individuals should be aware that the experimental therapy requires intensive psychological support during the dosing process.
The takeaway
The research suggests that optimized dosing of synthetic compounds could significantly change the landscape for treating major depression. As the 8 mg dose proceeds to phase 3 trials, patients and providers should monitor future results for signs of broader clinical availability.
Further reading
Learn more about the latest research in the field at Substance Abuse.
Live Poll
Should psychedelic-based drugs be approved as standard treatments for treatment-resistant depression?
